Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat CTC: Trastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells
2009-017485-23Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Trastuzumab arm with Observation arm (2 arms). Primary endpoint: Difference in CTC detection rate at week 18. Started Jan 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-017485-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017485-23.